Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBITDA Margin (2016 - 2026)

Intellia Therapeutics has reported EBITDA Margin over the past 12 years, most recently at 647.95% for Q1 2026.

  • Quarterly EBITDA Margin rose 3695.0% to 647.95% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 599.0% through Mar 2026, up 55070.0% year-over-year, with the annual reading at 609.22% for FY2025, 28628.0% up from the prior year.
  • EBITDA Margin was 647.95% for Q1 2026 at Intellia Therapeutics, down from 415.97% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 6825.61% in Q4 2023 and troughed at 2115.61% in Q2 2024.
  • The 5-year median for EBITDA Margin is 780.13% (2023), against an average of 458.41%.
  • Year-over-year, EBITDA Margin soared 2308287bps in 2022 and then tumbled -784775bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 821.48% in 2022, then skyrocketed by 931bps to 6825.61% in 2023, then tumbled by -115bps to 1022.14% in 2024, then soared by 59bps to 415.97% in 2025, then tumbled by -56bps to 647.95% in 2026.
  • Per Business Quant, the three most recent readings for NTLA's EBITDA Margin are 647.95% (Q1 2026), 415.97% (Q4 2025), and 732.75% (Q3 2025).